Intellectual property portfolio now includes 188 Patents and 131 Trademarks providing robust protection for the Company's product platforms

知识产权组合现在包括188项专利和131项商标，为公司的产品平台提供了强有力的保护

ANN ARBOR, MI / ACCESSWIRE / May 2, 2024 / Zomedica Corp. (NYSE American:ZOM) ('Zomedica' or the 'Company'), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the issuance of three new patents, bolstering the intellectual property protection for its revolutionary TRUFORMA diagnostic platform.

密歇根州安阿伯/ACCESSWIRE/2024年5月2日/Zomedica Corp.（纽约证券交易所美国代码：ZOM）（“Zomedica”或“公司”）是一家为马和伴侣动物提供即时诊断和治疗产品的兽医保健公司，今天宣布发布三项新专利，以加强其革命性TRUFORMA诊断平台的知识产权保护。

The TRUFORMA system provides veterinary professionals with reference laboratory accuracy directly at the point of care, enhancing the health management of horses and companion animals..

TRUFORMA系统直接在护理点为兽医专业人员提供参考实验室准确性，增强了马和伴生动物的健康管理。。

TRUFORMA technology represents a breakthrough in veterinary health diagnostics, employing highly sensitive proprietary Bulk Acoustic Wave (BAW) technology in a compact, easy-to-use device. This system utilizes disposable cartridges that are preloaded with reagents to minimize sample preparation and simplify the workflow, allowing veterinarians to deliver timely and accurate diagnostic results at the point of care.

TRUFORMA技术是兽医健康诊断领域的一项突破，它在一种紧凑、易于使用的设备中采用了高灵敏度的专有体声波（BAW）技术。该系统利用预装有试剂的一次性药筒，以最大程度地减少样品制备并简化工作流程，使兽医能够在护理点提供及时准确的诊断结果。

This supports more confident decision-making in clinical environments, primarily benefiting small animal practices and equine or mixed veterinary practices..

这有助于在临床环境中做出更有信心的决策，主要有利于小动物实践和马或混合兽医实践。。

The newly patents issued include innovations in the TRUFORMA® cartridge design and functionality:

新发布的专利包括TRUFORMA®墨盒设计和功能的创新：

U.S. Patent 11,933,793 B2 issued for Two Part Assembly

U、 美国专利11933793 B2由两部分组成

U.S. Patent 11, 940,414 issued for Crowded Sensor

U、 针对拥挤传感器发布的美国专利11940414

U.S. Patent 11,940,415 B2 issued for Fluidic Device with Fluid Port Orthogonal to Functionalized Active Region

U、 美国专利11940415 B2，用于流体端口与功能化活性区正交的流体装置

Ashley Wood, PhD, Zomedica's Vice President of Research & Development, stated, 'These patents cover innovations that enable the TRUFORMA system to detect a wider array of health conditions, from thyroid and adrenal disorders to gastrointestinal and pancreatic diseases, swiftly and with great precision, empowering veterinarians to enhance the quality of care they provide, which is at the heart of everything we do at Zomedica.'.

Zomedica研究与开发副总裁Ashley Wood博士表示，“这些专利涵盖的创新使TRUFORMA系统能够快速准确地检测更广泛的健康状况，从甲状腺和肾上腺疾病到胃肠道和胰腺疾病，使兽医能够提高他们提供的护理质量，这是我们在Zomedica所做一切的核心。”。

With the addition of these patents, Zomedica now holds a total of 65 U.S. patents and 123 international patents, with 33 U.S. and 98 foreign trademarks, strengthening the Company's market position. The Company additionally has 62 patent applications pending in the U.S. and abroad.

加上这些专利，Zomedica目前共拥有65项美国专利和123项国际专利，拥有33项美国商标和98项外国商标，巩固了公司的市场地位。该公司在美国和国外还有62项专利申请正在申请中。

'The addition of these new patents to our portfolio is a testament to Zomedica's innovative spirit and dedication to veterinary excellence,' stated Larry Heaton, Chief Executive Officer of Zomedica. 'These new patents not only expand our intellectual property portfolio but also reinforce our capability to deliver industry-leading diagnostic solutions.

Zomedica首席执行官拉里·希顿（LarryHeaton）表示：“将这些新专利添加到我们的投资组合中，证明了Zomedica的创新精神和对兽医卓越的奉献精神。”这些新专利不仅扩大了我们的知识产权组合，而且增强了我们提供业界领先的诊断解决方案的能力。

Our TRUFORMA platform is setting a new standard in veterinary care, providing unique assays not possible with other point of care analyzers, and empowering vets with the tools they need to diagnose and treat animals more effectively at the point of care.'.

我们的TRUFORMA平台正在制定兽医护理的新标准，提供其他护理点分析仪无法实现的独特检测，并为兽医提供在护理点更有效地诊断和治疗动物所需的工具。”。

The total addressable market for Zomedica's diagnostic and therapeutic products is estimated at $2.5 billion annually. The Company's potential customer base for TRUFORMA installations is expansive, including approximately 4,450 equine or mixed veterinary practices and 30,000 small animal veterinary practices across the United States, in a veterinary services market estimated at $62 billion..

Zomedica诊断和治疗产品的总目标市场估计每年为25亿美元。该公司TRUFORMA装置的潜在客户基础广阔，包括全美约4450家马或混合兽医诊所和30000家小动物兽医诊所，兽医服务市场估计为620亿美元。。

About Zomedica

关于Zomedica

Based in Ann Arbor, Michigan, Zomedica (NYSE American:ZOM) is a veterinary health company creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. Zomedica's product portfolio includes innovative diagnostics and medical devices that emphasize patient health and practice health.

Zomedica（纽约证券交易所美国代码：ZOM）是一家兽医保健公司，总部位于密歇根州安阿伯，专注于临床兽医未满足的需求，为马、狗和猫创造产品。Zomedica的产品组合包括强调患者健康和实践健康的创新诊断和医疗设备。

Zomedica's mission is to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit www.zomedica.com..

Zomedica的使命是为兽医提供提高生产力和增加收入的机会，同时更好地为他们护理的动物服务。有关更多信息，请访问www.zomedica.com。。

Follow Zomedica

跟随Zomedica

Email Alerts: http://investors.zomedica.com

电子邮件警报：http://investors.zomedica.com

LinkedIn: https://www.linkedin.com/company/zomedica

LinkedIn: https://www.linkedin.com/company/zomedica

Facebook: https://m.facebook.com/zomedica

脸谱网：https://m.facebook.com/zomedica

X (formerly Twitter): https://twitter.com/zomedica

X（以前的Twitter）：https://twitter.com/zomedica

Instagram: https://www.instagram.com/zomedica_inc

Instagram: https://www.instagram.com/zomedica_inc

Cautionary Note Regarding Forward-Looking Statements

关于前瞻性声明的注意事项

Except for statements of historical fact, this news release contains certain 'forward-looking information' or 'forward-looking statements' (collectively, 'forward-looking information') within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as 'plan', 'expect', 'project', 'intend', 'believe', 'anticipate', 'estimate' and other similar words, or statements that certain events or conditions 'may' or 'will' occur and include statements relating to our expectations regarding future results.

除历史事实声明外，本新闻稿包含适用证券法含义内的某些“前瞻性信息”或“前瞻性声明”（统称“前瞻性信息”）。前瞻性信息通常以“计划”、“期望”、“项目”、“打算”、“相信”、“预期”、“估计”等类似词语为特征，或陈述某些事件或条件“可能”或“将”发生，并包括与我们对未来结果的期望有关的陈述。

Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information..

虽然我们认为前瞻性信息中反映的期望是合理的，但不能保证这些期望会被证明是正确的。我们不能保证未来的结果、表现或成就。因此，没有人表示取得的实际结果将与前瞻性信息中规定的结果完全或部分相同。。

Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements, our ability to realize upon our business plans and cost control efforts and the impact of COVID-19 on our business, results and financial condition..

前瞻性信息基于报表编制之日管理层的意见和估计，包括有关经济增长、对公司产品的需求、公司生产和销售产品的能力、我们预算资本和运营支出的充足性、我们的战略合作伙伴对其在我们的商业协议下的义务的满意度、我们实现业务计划和成本控制工作的能力以及新型冠状病毒对我们的业务、业绩和财务状况的影响的假设。。

Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to successfully integrate acquisitions; uncertainty as to our ability to supply products in response to customer demand; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining .

我们的前瞻性信息受到各种风险和不确定性以及其他因素的影响，这些因素可能导致实际事件或结果与前瞻性信息中预期的结果存在重大差异。可能导致结果与前瞻性信息中表达的结果存在重大差异的一些风险和其他因素包括但不限于：临床研究的结果、普遍接受的会计原则的应用，这些因素非常复杂，涉及许多主观假设、估计和判断，以及我们的战略和业务计划是否会产生预期收益的不确定性；开发工作以及验证和确认研究的时间和结果的不确定性；商业化努力的时间和结果以及商业化努力的成本（包括发展内部销售队伍和管理我们的增长的成本）的不确定性；我们成功整合收购的能力不确定；我们根据客户需求提供产品的能力不确定；任何所需监管批准的可能性和时间以及资本的可用性和成本的不确定性；识别和开发新产品和技术并取得商业成功的能力；兽医对我们产品的认可；来自相关产品的竞争；维持和改进产品和服务质量所需的支出水平；技术变化和法律法规变化；我们确保和维持战略关系的能力；我们的战略合作伙伴履行其在我们的商业协议下的义务，包括产品制造义务；相关风险。

The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation.

本警示声明明确限定了本新闻稿中包含的前瞻性信息。我们没有义务更新任何前瞻性信息，以使这些信息符合实际结果或我们预期的变化，除非适用的证券法规另有要求。

Readers are cautioned not to place undue reliance on forward-looking information..

提醒读者不要过度依赖前瞻性信息。。

Investor Relations Contact:

投资者关系联系人：

Zomedica Investor Relations

Zomedica投资者关系

investors@zomedica.com

investors@zomedica.com

1-734-369-2555

1-734-369-2555

SOURCE: Zomedica Corp.

资料来源：Zomedica Corp。

View the original press release on accesswire.com

在accesswire.com上查看原始新闻稿